Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Difference in strain pathogenicity of a septicemic Yersinia pestis infection in a TLR2-/- mouse model.

O'Donnell KL, Knopick PL, Larsen R, Sarkar S, Nilles ML, Bradley DS.

Infect Immun. 2020 Jan 6. pii: IAI.00792-19. doi: 10.1128/IAI.00792-19. [Epub ahead of print]

PMID:
31907194
2.

Zika Virus-Specific IgY Results Are Therapeutic Following a Lethal Zika Virus Challenge without Inducing Antibody-Dependent Enhancement.

O'Donnell KL, Meberg B, Schiltz J, Nilles ML, Bradley DS.

Viruses. 2019 Mar 26;11(3). pii: E301. doi: 10.3390/v11030301.

3.

Necroptosis of infiltrated macrophages drives Yersinia pestis dispersal within buboes.

Arifuzzaman M, Ang WXG, Choi HW, Nilles ML, St John AL, Abraham SN.

JCI Insight. 2018 Sep 20;3(18). pii: 122188. doi: 10.1172/jci.insight.122188. eCollection 2018 Sep 20.

4.

Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.

Fink AL, Williams KL, Harris E, Alvine TD, Henderson T, Schiltz J, Nilles ML, Bradley DS.

PLoS Negl Trop Dis. 2017 Jul 7;11(7):e0005721. doi: 10.1371/journal.pntd.0005721. eCollection 2017 Jul.

5.
6.

Identification of the Targets of Type III Secretion System Inhibitors.

Condry DL, Nilles ML.

Methods Mol Biol. 2017;1531:203-211.

PMID:
27837494
8.

Expression and Purification of N-Terminally His-Tagged Recombinant Type III Secretion Proteins.

Alvine TD, Osei-Owusu P, Condry DL, Nilles ML.

Methods Mol Biol. 2017;1531:183-191.

PMID:
27837492
10.

Analysis of Type III Secretion System Secreted Proteins.

Condry DL, Nilles ML.

Methods Mol Biol. 2017;1531:93-99.

PMID:
27837484
11.

Isolation of Type III Secretion System Needle Complexes by Shearing.

Nilles ML, Condry DL, Osei-Owusu P.

Methods Mol Biol. 2017;1531:61-70.

PMID:
27837481
12.
13.

Blue Native Protein Electrophoresis to Study the T3S System Using Yersinia pestis as a Model.

Henderson TA, Nilles ML.

Methods Mol Biol. 2017;1531:33-46.

PMID:
27837479
14.

Introduction to Type III Secretion Systems.

Condry DL, Nilles ML.

Methods Mol Biol. 2017;1531:1-10. Review.

PMID:
27837477
15.

Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure.

Haese N, Brocato RL, Henderson T, Nilles ML, Kwilas SA, Josleyn MD, Hammerbeck CD, Schiltz J, Royals M, Ballantyne J, Hooper JW, Bradley DS.

PLoS Negl Trop Dis. 2015 Jun 5;9(6):e0003803. doi: 10.1371/journal.pntd.0003803. eCollection 2015.

16.

The N terminus of type III secretion needle protein YscF from Yersinia pestis functions to modulate innate immune responses.

Osei-Owusu P, Jessen Condry DL, Toosky M, Roughead W, Bradley DS, Nilles ML.

Infect Immun. 2015 Apr;83(4):1507-22. doi: 10.1128/IAI.02687-14. Epub 2015 Feb 2.

17.

Type III secretion needle proteins induce cell signaling and cytokine secretion via Toll-like receptors.

Jessen DL, Osei-Owusu P, Toosky M, Roughead W, Bradley DS, Nilles ML.

Infect Immun. 2014 Jun;82(6):2300-9. doi: 10.1128/IAI.01705-14. Epub 2014 Mar 18.

18.

A type III secretion system inhibitor targets YopD while revealing differential regulation of secretion in calcium-blind mutants of Yersinia pestis.

Jessen DL, Bradley DS, Nilles ML.

Antimicrob Agents Chemother. 2014;58(2):839-50. doi: 10.1128/AAC.01170-13. Epub 2013 Nov 18.

19.

Resistance to Yersinia pestis infection decreases with age in B10.T(6R) mice.

Lambert ND, Langfitt DM, Nilles ML, Bradley DS.

Infect Immun. 2011 Nov;79(11):4438-46. doi: 10.1128/IAI.05267-11. Epub 2011 Aug 22.

20.

LcrG secretion is not required for blocking of Yops secretion in Yersinia pestis.

Reina LD, O'Bryant DM, Matson JS, Nilles ML.

BMC Microbiol. 2008 Feb 8;8:29. doi: 10.1186/1471-2180-8-29.

21.

Resistance of Yersinia pestis to complement-dependent killing is mediated by the Ail outer membrane protein.

Bartra SS, Styer KL, O'Bryant DM, Nilles ML, Hinnebusch BJ, Aballay A, Plano GV.

Infect Immun. 2008 Feb;76(2):612-22. Epub 2007 Nov 19.

22.

Roles of YopN, LcrG and LcrV in controlling Yops secretion by Yersinia pestis.

Hamad MA, Nilles ML.

Adv Exp Med Biol. 2007;603:225-34. Review.

PMID:
17966419
23.

Structure-function analysis of the C-terminal domain of LcrV from Yersinia pestis.

Hamad MA, Nilles ML.

J Bacteriol. 2007 Sep;189(18):6734-9. Epub 2007 Jul 20.

24.

Immunization of mice with YscF provides protection from Yersinia pestis infections.

Matson JS, Durick KA, Bradley DS, Nilles ML.

BMC Microbiol. 2005 Jun 24;5:38.

25.

Dissecting the structure of LcrV from Yersinia pestis, a truly unique virulence protein.

Nilles ML.

Structure. 2004 Mar;12(3):357-8. No abstract available.

26.
27.

Genome sequence of Yersinia pestis KIM.

Deng W, Burland V, Plunkett G 3rd, Boutin A, Mayhew GF, Liss P, Perna NT, Rose DJ, Mau B, Zhou S, Schwartz DC, Fetherston JD, Lindler LE, Brubaker RR, Plano GV, Straley SC, McDonough KA, Nilles ML, Matson JS, Blattner FR, Perry RD.

J Bacteriol. 2002 Aug;184(16):4601-11.

28.

Interaction of the Yersinia pestis type III regulatory proteins LcrG and LcrV occurs at a hydrophobic interface.

Matson JS, Nilles ML.

BMC Microbiol. 2002 Jun 28;2:16. Erratum in: BMC Microbiol. 2002 Sep 5;2(1):25..

29.
30.

Virulence role of V antigen of Yersinia pestis at the bacterial surface.

Fields KA, Nilles ML, Cowan C, Straley SC.

Infect Immun. 1999 Oct;67(10):5395-408.

31.
32.

Supplemental Content

Loading ...
Support Center